- Home
- URGN vs BFK Comparison
URGN vs BFK Comparison
Compare URGN & BFK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- BFK
- Stock Information
- Founded
- URGN 2004
- BFK N/A
- Country
- URGN United States
- BFK United States
- Employees
- URGN N/A
- BFK N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- BFK Finance Companies
- Sector
- URGN Health Care
- BFK Finance
- Exchange
- URGN Nasdaq
- BFK Nasdaq
- Market Cap
- URGN 465.9M
- BFK 436.4M
- IPO Year
- URGN 2017
- BFK N/A
- Fundamental
- Price
- URGN $11.06
- BFK $9.97
- Analyst Decision
- URGN Strong Buy
- BFK
- Analyst Count
- URGN 6
- BFK 0
- Target Price
- URGN $40.75
- BFK N/A
- AVG Volume (30 Days)
- URGN 418.3K
- BFK 117.1K
- Earning Date
- URGN 03-10-2025
- BFK 01-01-0001
- Dividend Yield
- URGN N/A
- BFK 4.33%
- EPS Growth
- URGN N/A
- BFK N/A
- EPS
- URGN N/A
- BFK N/A
- Revenue
- URGN $90,398,000.00
- BFK N/A
- Revenue This Year
- URGN $43.60
- BFK N/A
- Revenue Next Year
- URGN $103.77
- BFK N/A
- P/E Ratio
- URGN N/A
- BFK N/A
- Revenue Growth
- URGN 9.29
- BFK N/A
- 52 Week Low
- URGN $9.03
- BFK $8.55
- 52 Week High
- URGN $20.70
- BFK $10.48
- Technical
- Relative Strength Index (RSI)
- URGN 50.86
- BFK 43.33
- Support Level
- URGN $11.12
- BFK $9.88
- Resistance Level
- URGN $11.91
- BFK $10.29
- Average True Range (ATR)
- URGN 0.57
- BFK 0.11
- MACD
- URGN -0.02
- BFK -0.00
- Stochastic Oscillator
- URGN 26.40
- BFK 23.26
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About BFK BlackRock Municipal Income Trust
Blackrock Municipal Income Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from regular U.S. federal income tax.